» Articles » PMID: 38419708

Utility and Limitations of EEG in the Diagnosis and Management of -related Pyridoxine-dependent Epilepsy. A Retrospective Observational Study

Overview
Journal Front Neurol
Specialty Neurology
Date 2024 Feb 29
PMID 38419708
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Pyridoxine-dependent epilepsy due to variants (PDE-ALDH7A1) is a rare disorder, presenting typically with severe neonatal, epileptic encephalopathy. Early diagnosis is imperative to prevent uncontrolled seizures. We have explored the role of EEG in the diagnosis and management of PDE.

Methods: A total of 13 Norwegian patients with PDE-ALDH7A1 were identified, of whom five had reached adult age. Altogether 163 EEG recordings were assessed, 101 from the 1st year of life.

Results: Median age at seizure onset was 9 h (IQR 41), range 1 h-6 days. Median delay from first seizure to first pyridoxine injection was 2 days (IQR 5.5). An EEG burst suppression pattern was seen in eight patients (62%) during the first 5 days of life. Eleven patients had recordings during pyridoxine injections: in three, immediate EEG improvement correlated with seizure control, whereas in six, no change of epileptiform activity occurred. Of these six, one had prompt clinical effect, one had delayed effect (< 1 day), one had no effect, one had uncertain effect, and another had more seizures. A patient without seizures at time of pyridoxine trial remained seizure free for 6 days. Two patients with prompt clinical effect had increased paroxysmal activity, one as a conversion to burst suppression. Autonomic seizures in the form of apnoea appeared to promote respiratory distress and were documented by EEG in one patient. EEG follow-up in adult age did not show signs of progressing encephalopathy.

Conclusion: A neonatal burst suppression EEG pattern should raise the suspicion of PDE-ALDH7A1. Respiratory distress is common; isolated apnoeic seizures may contribute. EEG responses during pyridoxine trials are diverse, often with poor correlation to immediate clinical effect. Reliance on single trials may lead to under-recognition of this treatable condition. Pyridoxine should be continued until results from biomarkers and genetic testing are available.

Citing Articles

Case report: Clinical and genetic characterization of a novel variant causing pyridoxine-dependent epilepsy, developmental delay, and intellectual disability in two siblings.

Salih M, AlBakheet A, Almass R, Hamed A, AlOdaib A, Kaya N Front Psychiatry. 2025; 15:1501238.

PMID: 39763688 PMC: 11701133. DOI: 10.3389/fpsyt.2024.1501238.

References
1.
Schmitt B, Baumgartner M, Mills P, Clayton P, Jakobs C, Keller E . Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency. Dev Med Child Neurol. 2010; 52(7):e133-42. DOI: 10.1111/j.1469-8749.2010.03660.x. View

2.
Shellhaas R . Neonatal seizures reach the mainstream: The ILAE classification of seizures in the neonate. Epilepsia. 2021; 62(3):629-631. DOI: 10.1111/epi.16857. View

3.
Jamali A, Kristensen E, Tangeraas T, Arntsen V, Sikiric A, Kupliauskiene G . The spectrum of pyridoxine dependent epilepsy across the age span: A nationwide retrospective observational study. Epilepsy Res. 2023; 190:107099. DOI: 10.1016/j.eplepsyres.2023.107099. View

4.
Nunes M, Yozawitz E, Zuberi S, Mizrahi E, Cilio M, Moshe S . Neonatal seizures: Is there a relationship between ictal electroclinical features and etiology? A critical appraisal based on a systematic literature review. Epilepsia Open. 2019; 4(1):10-29. PMC: 6398099. DOI: 10.1002/epi4.12298. View

5.
Beniczky S, Aurlien H, Brogger J, Hirsch L, Schomer D, Trinka E . Standardized computer-based organized reporting of EEG: SCORE - Second version. Clin Neurophysiol. 2017; 128(11):2334-2346. DOI: 10.1016/j.clinph.2017.07.418. View